Citations

Background: The purpose of this study was to investigate the association between cannabis use and postoperative complications following ankle and hindfoot arthrodesis. Methods: A retrospective cohort study using a large national insurance database from 2010 to 2022 was conducted. All patients who underwent ankle or hindfoot arthrodesis with at least 2 years’ follow-up were included. Patients were divided into 4 groups: cannabis-only users, tobacco-only users, cannabis and tobacco users, and nonuser controls. Groups were matched 1:4 with nonuser controls based on demographic variables and comorbidities. Also, both cannabis and tobacco users were matched 1:4 with tobacco-only users based on demographics and comorbidities. Medical complications within 90 days of surgery and surgery-specific complications within 2 years were compared between groups with multivariable logistic regressions. Results: Compared with nonuser controls, cannabis users only were not at increased risk of 90-day medical complications or 2-year surgical complications. Tobacco use alone was associated with increased risk of postoperative admission (OR 1.32, 95% CI 1.21-1.43) and emergency department (ED) utilization (OR 1.57, 95% CI 1.48-1.66) within 90 days as well as infection (OR 1.24, 95% CI 1.18-1.30), hardware removal (OR 1.12, 95% CI 1.07-1.18), nonunion (OR 1.33, 95% CI 1.27-1.40), and wound dehiscence (OR 1.38, 95% CI 1.27-1.49) within 2 years of surgery compared with nonuser controls. Compared with tobacco-only use, combined cannabis and tobacco use was associated with increased risk of ED visits within 90 days (OR 1.45, 95% CI 1.30-1.62) and nonunion within 2 years of surgery (OR 1.19, 95% CI 1.05-1.35). Conclusion: These findings suggest that although cannabis use alone was not associated with a higher risk of postoperative complications, its concurrent use with tobacco was linked to greater rates of adverse outcomes. Level of Evidence: Level III, retrospective case control study.

PURPOSE Adjuvant endocrine therapy (ET) improves overall survival (OS) in estrogen receptor (ER)–positive early-stage breast cancer (BC). However, the benefit of ET for those with ER-low BC (ER 1%-10%) is unclear. METHODS Using the National Cancer Database, we studied patients with high-risk stage I to III, ER-low BC (defined as immunohistochemistry 1%-10%) who received (neo)adjuvant chemotherapy and did or did not initiate ET. OS was analyzed with ET initiation as a time-dependent covariate using Cox proportional hazards regression. RESULTS Of 10,362 patients with stage I to III ER-low BC, 7,018 received chemotherapy and met inclusion criteria. ET omission was 42% at 12 months and more common in patients with tumors that were progesterone receptor–negative, human epidermal growth factor receptor 2–negative, higher-grade (grade 2/3) and higher Ki-67 (≥20%; all P < .001) and those who received neoadjuvant chemotherapy (NAC; P < .001). With a median follow-up of 3 years, 586 deaths were observed. In a multivariable analysis, ET omission was associated with a higher risk of death (hazard ratio [HR], 1.23 [95% CI, 1.04 to 1.46]; P = .02), with a greater impact in those with higher ER levels: ER 1%-5% (HR, 1.15 [95% CI, 0.91 to 1.45]; P = .24) versus ER 6%-10% (HR, 1.42 [95% CI, 1.00 to 2.02]; P = .048). Among patients treated with NAC (n = 4,377, 62%), ET omission was associated with worse OS in those with residual disease (RD; HR, 1.26 [95% CI, 1.00 to 1.57]; P = .046) but not in those who achieved a pathologic complete response (HR, 1.06 [95% CI, 0.62 to 1.80]; P = .84). CONCLUSION In ER-low, early-stage BC, ET omission is associated with significantly worse OS, especially in patients with RD after NAC and those with higher (6%-10%) ER levels. Until prospective data are available, patients with ER-low BC should be counseled regarding the potential benefit of ET.

PURPOSE Monitoring with electronic patient-reported outcome (ePRO) systems can improve cancer outcomes and is increasingly recommended. Optimal implementations of ePROs in routine clinical care are not yet known. Perspectives from clinicians, clinic staff, and patients who used ePROs can provide real-world insights for optimizing the design, efficiency, and effectiveness of future implementations. METHODS Providers, clinic staff, and patients receiving treatment for metastatic cancer from community oncology practices that implemented ePROs as part of the national PRO-TECT trial (Alliance AFT-39) participated in semi-structured interviews related to ePROs. Perceptions from clinicians on perceived benefits, usefulness, acceptability, impact on quality of care, and required effort; from staff on clinical integration and effort; and from patients on ease of use, usefulness, and effort were collected. Themes, subthemes, and recommendations were identified via a standardized coding-based directed thematic analytic approach. RESULTS Ninety-eight clinic members and 67 patients participated from 25 intervention sites. Four themes were identified: (1) positive impact of ePROs on cancer care quality, communication, and relationship-building; (2) ePRO system usability; (3) challenges to ePRO integration with clinical workflow; and (4) recommendations for improving ePRO systems and implementation. Subthemes related to the impact of ePROs on cancer care included enhanced communication with care team, increased awareness of symptoms, and increased ability to self-manage symptoms. Actionable recommendations for future initiatives were to engage and train clinicians, staff, and organizational support for ePRO-related activities; tailor content of ePRO surveys to be clinically actionable; integrate ePRO alert notifications and reports with existing information systems; and optimize integration of ePROs with existing clinic workflow processes. CONCLUSION Experiences of care team members and patients were positive, with actionable recommendations identified to guide future ePRO implementations.

Abstract This single authored textbook serves as a comprehensive guide to manage all aspects of critically ill neurologic patients. The book is richly illustrated and with a succinct text closely edited for relevance. It accurately describes the immediacy and rapid-fire decisions that comprise the work life and environment of the neurointensivist. The Practice of Emergency and Critical Care Neurology follows patients from the very moment they enter the emergency department—where the neurologist makes on-the-spot decisions—to their admission to the neurologic intensive care unit—where mostly specialists in the neurosciences assume full responsibility for patient care. This book differs from conventional textbooks by specifically following the time course of clinical complexities as they emerge and change. Great emphasis is placed on management of unstable and deteriorating patients.

ABSTRACT Objective Although fetal sex chromosome complement prediction by prenatal cell‐free DNA (cfDNA) screening is highly accurate, discordance between the cfDNA‐inferred chromosomal sex and phenotypic sex observed via ultrasonography or at birth, that is, “fetal sex discordance”, does rarely occur. Such discordance may be caused by differences in sex development (DSD) or technical or biological artifacts. This study aims to provide insights into the proportion of fetal sex discordance cases caused by DSD versus non‐DSD artifacts. Method We retrospectively reviewed 122,748 cases that underwent diagnostic testing at the Mayo Clinic Cytogenetics Laboratory between 2015 and 2023. Thirty‐three singleton‐gestation cases tested for fetal sex discordances were identified. Results Fetal sex discordance was attributed to non‐DSD artifacts in 24 (73%) of the 33 patients. In these cases, the phenotypic sex matched the chromosomal sex revealed by diagnostic cytogenetic testing. The remaining 9 patients included one with mosaic 46,X,psu idic(Y)(q11.21)/45,X, 5 with 46,XY DSD, and 3 with 46,XX DSD. Conclusion The majority of fetal sex discordance cases are caused by non‐DSD artifacts rather than DSD. Accurate clinical counseling of fetal sex discordance requires distinguishing between DSD and non‐DSD causes, emphasizing the need for diagnostic cytogenetic testing.

ABSTRACT Background As Coccidioides spp. are endemic in the southwestern United States, awareness of the risk factors for severe disease and dissemination is important to avoid delays in diagnosis and treatment. In addition to immunocompetent patients, individuals of certain ethnic backgrounds, especially African and Filipino ancestry, are at higher risk for dissemination. Diagnostic testing may be complicated by the lack of available invasive specimens for histopathologic examination and culture. Case Summary A 29-year-old African American woman presented with a 6-year history of abdominal bloating and discomfort, which was previously diagnosed as endometriosis and possible irritable bowel syndrome. After multiple visits to primary care, urgent care, and emergency settings, she was referred for outpatient gynecology and gastrointestinal follow-up. Imaging revealed diffuse peritoneal nodules potentially concerning for malignancy, and biopsies revealed Coccidioides spp. spherules on the frozen section. Routine bacterial and fungal cultures from the biopsied nodules grew Coccidioides immitis/posadasii . The patient was placed on fluconazole with rapid symptom resolution and was maintained on fluconazole at a 2-year follow-up. Conclusion The case presented highlights a reasonably common occurrence in endemic regions—the delayed diagnosis of coccidioidomycosis due to the lack of consideration as the etiology of the patient’s symptoms. This patient was at risk for dissemination due to her ethnicity, and while the differential for her presenting symptoms was broad, coccidioidomycosis should have been considered. In immunocompetent patients, like the case presented, serologic testing should be pursued, as severe or disseminated cases typically have positive IgG responses.

ABSTRACTThe optimal conditioning schedule and CD34+ cell dose for autologous stem cell transplantation (ASCT) for AL amyloidosis is unknown. Patients (n = 1704) who underwent ASCT for AL amyloidosis between 2003 and 2020 in 9 centers were included. Data on melphalan conditioning dose, number of conditioning days, whether a rest day between conditioning and stem cell infusion was given or not, and infused CD34+ cell dose were collected. Full‐dose melphalan (≥ 180 mg/m2) was administered in 63.7% of the patients, and 80.4% had melphalan split into 2‐day conditioning. A rest day (day −1) between the conditioning regimen and stem cell infusion was provided in 52.5% of patients. The median infused CD34+ cell count was 4.7 × 106/kg. An infused CD34+ cell count ≥ 4.5 × 106/kg was associated with a shorter time to neutrophil and platelet engraftment. In a nominal regression analysis, full‐dose melphalan, 1‐day melphalan conditioning, and omitting a rest day between conditioning and stem cell infusion were independent predictors of post‐ASCT higher deep hematological response. The median follow‐up was 8.6 years, and 38% of patients died. Independent predictors of superior overall survival in multivariate Cox regression analysis included full‐dose melphalan, having no rest day, and infused CD34+ cells ≥ 4.5 × 106/kg. Independent predictors of higher day‐100 transplant‐related mortality (TRM) in nominal logistic regression analysis included poorer performance status, NT‐proBNP/BNP ≥ 1800/400 pg/mL, serum albumin < 2.5 g/dL, CD34+ cells < 4.5 × 106/kg, and not having a rest day. In conclusion, 1 day of melphalan conditioning and administration of CD34+ cells ≥ 4.5 × 106/kg are recommended for ASCT in AL amyloidosis.

AbstractIntermittent hypoxia has been used to enhance oxygen delivery in athletes and patients; however, it is unclear whether acute exposure is sufficient to elicit lasting physiologic adaptation(s). The purpose of this study was to evaluate physiologic response(s) to hypobaric‐hypoxic (HH) exercise. Nine participants (4 M/5F; 37.9 ± 12.7 yrs.; 174.3 ± 9.4 cm; 75.3 ± 15.9 kg; 24.4 ± 3.4 kg/m2) were exposed to progressively higher simulated altitudes and completed two HH submaximal exercise sessions (~30 min ea., ≥72 h apart) on a cycle ergometer at the first altitude that posed a significant challenge to them. Altitude was dependent on individual response as determined from heart rate (HR), peripheral oxygenation (SpO2), and the ratio of HR response to SpO2 (HR/SpO2). Statistical analyses included paired samples t‐test (p ≤ 0.05). No significant change in SpO2 (HH‐1: 85 ± 4% vs. HH‐2: 85 ± 4%, p = 0.684) was observed between sessions. However, there were significant decreases in: HR (HH‐1: 150 ± 18 bpm vs. HH‐2: 133 ± 27 bpm, p = 0.001) of 18 bpm (11%); HR/SpO2 (HH‐1: 1.76 ± 0.22 vs. HH‐2: 1.57 ± 0.33, p = 0.012); and RPE (HH‐1: 15 ± 2 vs. HH‐2: 11 ± 4, p = 0.017). While workload significantly increased (HH‐1: 89 ± 36 W vs. HH‐2: 105 ± 36 W, p = 0.024). Some participants had a threshold/challenging altitude, but from a single bout there is evidence of improved tolerance that can last over a week. Further investigation is required to replicate and understand possible mechanisms.